Results 21 to 30 of about 9,288,830 (350)
Endocrine Toxicities of Antineoplastic Therapy [PDF]
In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...]
Puliani G., Appetecchia M.
openaire +3 more sources
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis.
F. Bidard +28 more
semanticscholar +1 more source
Summary Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2 ...
S. Johnston +23 more
semanticscholar +1 more source
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended
L. Korde +16 more
semanticscholar +1 more source
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
BACKGROUND Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.
A. Partridge +38 more
semanticscholar +1 more source
PurposeThe purpose of this study was to evaluate endocrine therapy and chemotherapy for first-line, maintenance, and second-line treatment of hormone receptor-positive HER-2-negative metastatic breast cancer (HR+HER-2-MBC) and the relationship between ...
Qiuyue Liu +6 more
doaj +1 more source
Purpose This systematic review aimed to determine the rate and identify correlates of adherence and persistence over five years of treatment with adjuvant endocrine therapy in female breast cancer patients.
Izzati Yussof +3 more
semanticscholar +1 more source
Omission of radiotherapy among older women taking 5 years of adjuvant endocrine therapy following breast conserving surgery for early-stage, hormone sensitive breast cancers is well-studied. However, endocrine therapy toxicities are significant, and many
Susan G. R. McDuff, Rachel C. Blitzblau
doaj +1 more source
Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
Simple Summary Five years of therapy remains the standard for adjuvant endocrine therapy in early breast cancer. However, the recurrence risk remains elevated beyond this time period.
I. Bekes, J. Huober
semanticscholar +1 more source
PurposeTo evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective ...
Eunae Jeong +4 more
doaj +1 more source

